Page 23 - ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SAN FRANCISCO and SUZHOU, China, July 11, 2021 /PRNewswire/  Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the first patient has been dosed in a Phase 1 study of IBI323, an anti-LAG-3/PD-L1 bispecific antibody. The objective of this open-label, multi-center Phase 1 dose escalation and expansion study is to evaluate the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI323 in patients with advanced malignant tumors whose cancer progressed on standard-of-care treatment. The trial is being conducted in China.

Hong kongAdimab incyteCaicun zhouEli lillyCancer institute of tongji university medical schoolClinical development of innoventDrug administrationMd anderson cancer centerInnovent biologics incInnovent biologicsOncology departmentShanghai pulmonary hospital affiliatedTongji universityCancer instituteTongji university medical schoolSenior vice president